Report cover image

Systemic Sclerosis Market Report and Forecast 2024-2032

Publisher Expert Market Research
Published Feb 13, 2024
Length 180 Pages
SKU # EMAR18558306

Description

Systemic Sclerosis Market Report and Forecast 2024-2032


Systemic Sclerosis Market Report and Forecast 2024-2032

Systemic Sclerosis Market Outlook

The systemic sclerosis market size is anticipated to grow at a CAGR of 6.3% during the forecast period of 2024-2032, driven by development of novel therapies targeting the underlying mechanisms of systemic sclerosis across the major markets.

Systemic Sclerosis: Introduction

Systemic sclerosis also known as scleroderma, is a rare chronic autoimmune disease characterized by the hardening and tightening of the skin and connective tissues. It affects not only the skin but also internal organs such as the heart, lungs, kidneys, and gastrointestinal tract, leading to various complications. Symptoms can include skin thickening, joint pain, digestive issues, and Raynaud's phenomenon. The exact cause of Systemic sclerosis is unknown, and treatment focuses on managing symptoms and preventing organ damage.

Key Trends in the Systemic Sclerosis Market

There's a global trend towards the development of novel therapies targeting the underlying mechanisms of systemic sclerosis. This includes research into immunosuppressants, biologics, and targeted therapies that aim to modulate the immune response and fibrotic processes characteristic of Systemic sclerosis. Clinical trials are exploring the efficacy of these new treatment approaches, offering hope for improved patient outcomes.

The market is seeing a shift towards personalized medicine, with treatments being tailored based on individual patient characteristics, disease subtypes, and severity. Biomarker research is gaining traction, aiming to identify patients who are more likely to respond to specific therapies. This approach seeks to optimize treatment effectiveness and reduce adverse effects.

There's an increasing emphasis on multidisciplinary care models to address the complex, multi-organ involvement in systemic sclerosis. Specialized centers that offer comprehensive care involving rheumatologists, dermatologists, pulmonologists, and other specialists are becoming more common. These centers focus on holistic patient management, integrating pharmacological treatments with physical therapy, patient education, and psychological support.

Awareness campaigns and patient advocacy groups are playing a vital role in increasing public and healthcare professional awareness of systemic sclerosis. These efforts are improving early diagnosis and access to care. Support networks provide valuable resources and emotional support for patients and their families, helping to navigate the challenges of living with Systemic sclerosis.

Given the rarity of systemic sclerosis, many treatments fall under orphan drug status, benefiting from regulatory incentives designed to encourage the development of drugs for rare diseases. This support facilitates research and development activities, expedites the approval process, and ultimately brings innovative treatments to the market more quickly.

Systemic Sclerosis Market Segmentation

Market Breakup by Diagnosis
  • Skin Biopsy
  • Imaging Techniques
  • Blood test
  • Electrocardiogram
  • Pulmonary Function Test
Market Breakup by Type
  • Limited Systemic Sclerosis
  • Diffuse Systemic Sclerosis
  • Sine Systemic Sclerosis
Market Breakup by Drug Class
  • Immunosuppressors
  • PDE-5 Inhibitors
  • Endothelin Receptor Antagonist
  • Prostacyclin Analogues
  • Others
Market Breakup by End User
  • Hospitals
  • Clinics
  • Research Institutes
  • Others
Market Breakup by Region
  • United States
  • EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Japan
Systemic Sclerosis Market Overview

In North America, the systemic sclerosis market is characterized by a strong focus on research and development of new treatments and a comprehensive approach to patient care. The region benefits from advanced healthcare infrastructure and a high level of awareness about autoimmune diseases. There's a significant emphasis on personalized medicine and the use of immunosuppressive drugs, alongside therapies targeting specific symptoms and organ involvement. Patient advocacy groups play a crucial role in supporting research and improving access to care.

Europe's market is driven by well-established healthcare systems and robust support for rare disease research, including systemic sclerosis. Collaborative research efforts across European countries aim to understand the disease better and develop more effective treatments. The European Medicines Agency (EMA) provides regulatory pathways for orphan drugs, facilitating the development of new therapies. Integrated care models, combining pharmacological treatments with physical therapy and psychological support, are essential aspects of managing the condition.

In Japan, the systemic sclerosis market benefits from a strong emphasis on healthcare innovation and a proactive approach to addressing rare diseases. The country has a well-developed healthcare system and policies supporting the development and approval of treatments for conditions like systemic sclerosis. Japan's market is notable for its focus on early diagnosis and the use of cutting-edge technologies and therapies. Research and clinical trials in Japan often explore novel therapeutic approaches, including stem cell therapy and targeted molecular treatments.

Systemic Sclerosis Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players.
  • F. Hoffmann La Roche Ltd.
  • Johnson & Johnson Services
  • United Therapeutics
  • Boehringer Ingelheim International GmbH
  • GlaxoSmithKline plc
  • Pfizer
  • Eli Lilly and Company
  • Bayer AG
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Gilead Sciences Inc
  • Novartis AG
  • Cumberland Pharmaceuticals
  • Organon LLC
  • Lupin Ltd.
We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

*Please Note:* The report will take 7 business days to complete, after order confirmation.

Table of Contents

180 Pages
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Systemic Sclerosis Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Systemic Sclerosis Epidemiology Analysis – Seven Major Markets
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Systemic Sclerosis Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Systemic Sclerosis Epidemiology Forecast (2017-2032)
5.3.1 Germany Systemic Sclerosis Epidemiology Forecast (2017-2032)
5.3.2 France Systemic Sclerosis Epidemiology Forecast (2017-2032)
5.3.3 Italy Systemic Sclerosis Epidemiology Forecast (2017-2032)
5.3.4 Spain Systemic Sclerosis Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Systemic Sclerosis Epidemiology Forecast (2017-2032)
5.4 Japan Systemic Sclerosis Epidemiology Forecast (2017-2032)
6 Systemic Sclerosis Market Overview – Seven Major Markets
6.1 Systemic Sclerosis Market Historical Value (2017-2023)
6.2 Systemic Sclerosis Market Forecast Value (2024-2032)
7 Systemic Sclerosis Market Landscape – Seven Major Markets
7.1 Systemic Sclerosis Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Systemic Sclerosis Product Landscape
7.2.1 Analysis by Products
7.2.2 Analysis by Indications
7.2.3 Analysis by Route of Administration
8 Systemic Sclerosis Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Systemic Sclerosis Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Systemic Sclerosis Market Segmentation – Seven Major Markets
11.1 Systemic Sclerosis Market by Diagnosis
11.1.1 Market Overview
11.1.2 Skin Biopsy
11.1.3 Imaging Techniques
11.1.4 Blood Test
11.1.5 Electrocardiogram
11.1.6 Pulmonary Function Test
11.2 Systemic Sclerosis Market by Type
11.2.1 Market Overview
11.2.2 Limited Systemic Sclerosis
11.2.3 Diffuse Systemic Sclerosis
11.2.4 Sine Systemic Sclerosis
11.3 Systemic Sclerosis Market by Drug Class
11.3.1 Market Overview
11.3.2 Immunosuppressors
11.3.3 PDE-5 Inhibitors
11.3.4 Endothelin Receptor Antagonist
11.3.5 Prostacyclin Analogues
11.3.6 Biologics
11.3.7 Others
11.4 Systemic Sclerosis Market by End User
11.4.1 Market Overview
11.4.2 Hospitals
11.4.3 Clinics
11.4.4 Research Institutes
11.4.5 Others
11.5 Systemic Sclerosis Market by Region
11.5.1 Market Overview
11.5.2 United States
11.5.3 EU-4 and the United Kingdom
11.5.3.1 Germany
11.5.3.2 France
11.5.3.3 Italy
11.5.3.4 Spain
11.5.3.5 United Kingdom
11.5.4 Japan
12 United States Systemic Sclerosis Market
12.1 Systemic Sclerosis Market Historical Value (2017-2023)
12.2 Systemic Sclerosis Market Forecast Value (2024-2032)
12.3 Systemic Sclerosis Market by Diagnosis
12.4 Systemic Sclerosis Market by Drug Class
13 EU-4 and United Kingdom Systemic Sclerosis Market
13.1 Systemic Sclerosis Market Historical Value (2017-2023)
13.2 Systemic Sclerosis Market Forecast Value (2024-2032)
13.3 Germany Systemic Sclerosis Market Overview
13.3.1 Systemic Sclerosis Market by Diagnosis
13.3.2 Systemic Sclerosis Market by Drug Class
13.4 France Systemic Sclerosis Market Overview
13.4.1 Systemic Sclerosis Market by Diagnosis
13.4.2 Systemic Sclerosis Market by Drug Class
13.5 Italy Systemic Sclerosis Market Overview
13.5.1 Systemic Sclerosis Market by Diagnosis
13.5.2 Systemic Sclerosis Market by Drug Class
13.6 Spain Systemic Sclerosis Market Overview
13.6.1 Systemic Sclerosis Market by Diagnosis
13.6.2 Systemic Sclerosis Market by Drug Class
13.7 United Kingdom Systemic Sclerosis Market Overview
13.7.1 Systemic Sclerosis Market by Diagnosis
13.7.2 Systemic Sclerosis Market by Drug Class
14 Japan Systemic Sclerosis Market
14.1 Systemic Sclerosis Market Historical Value (2017-2023)
14.2 Systemic Sclerosis Market Forecast Value (2024-2032)
14.2.1 Systemic Sclerosis Market by Diagnosis
14.2.2 Systemic Sclerosis Market by Drug Class
15 Patent Analysis
15.1 Analysis by Type of Patent
15.2 Analysis by Publication year
15.3 Analysis by Issuing Authority
15.4 Analysis by Patent Age
15.5 Analysis by CPC Analysis
15.6 Analysis by Patent Valuation
15.7 Analysis by Key Players
16 Grants Analysis
16.1 Analysis by year
16.2 Analysis by Amount Awarded
16.3 Analysis by Issuing Authority
16.4 Analysis by Grant Application
16.5 Analysis by Funding Institute
16.6 Analysis by NIH Departments
16.7 Analysis by Recipient Organization
17 Clinical Trials Analysis
17.1 Analysis by Trial Registration Year
17.2 Analysis by Trial Status
17.3 Analysis by Trial Phase
17.4 Analysis by Therapeutic Area
17.5 Analysis by Geography
18 Funding Analysis
18.1 Analysis by Funding Instances
18.2 Analysis by Type of Funding
18.3 Analysis by Funding Amount
18.4 Analysis by Leading Players
18.5 Analysis by Leading Investors
18.6 Analysis by Geography
19 Partnership and Collaborations Analysis
19.1 Analysis by Partnership Instances
19.2 Analysis by Type of Partnership
19.3 Analysis by Leading Players
19.4 Analysis by Geography
20 Supplier Landscape
20.1 F. Hoffmann La Roche Ltd.
20.1.1 Financial Analysis
20.1.2 Product Portfolio
20.1.3 Demographic Reach and Achievements
20.1.4 Mergers and Acquisition
20.1.5 Certifications
20.2 Johnson & Johnson Services
20.2.1 Financial Analysis
20.2.2 Product Portfolio
20.2.3 Demographic Reach and Achievements
20.2.4 Mergers and Acquisition
20.2.5 Certifications
20.3 United Therapeutics
20.3.1 Financial Analysis
20.3.2 Product Portfolio
20.3.3 Demographic Reach and Achievements
20.3.4 Mergers and Acquisition
20.3.5 Certifications
20.4 Boehringer Ingelheim International GmbH
20.4.1 Financial Analysis
20.4.2 Product Portfolio
20.4.3 Demographic Reach and Achievements
20.4.4 Mergers and Acquisition
20.4.5 Certifications
20.5 GlaxoSmithKline plc
20.5.1 Financial Analysis
20.5.2 Product Portfolio
20.5.3 Demographic Reach and Achievements
20.5.4 Mergers and Acquisition
20.5.5 Certifications
20.6 Pfizer
20.6.1 Financial Analysis
20.6.2 Product Portfolio
20.6.3 Demographic Reach and Achievements
20.6.4 Mergers and Acquisition
20.6.5 Certifications
20.7 Eli Lilly and Company
20.7.1 Financial Analysis
20.7.2 Product Portfolio
20.7.3 Demographic Reach and Achievements
20.7.4 Mergers and Acquisition
20.7.5 Certifications
20.8 Bayer AG
20.8.1 Financial Analysis
20.8.2 Product Portfolio
20.8.3 Demographic Reach and Achievements
20.8.4 Mergers and Acquisition
20.8.5 Certifications
20.9 Mylan N.V.
20.9.1 Financial Analysis
20.9.2 Product Portfolio
20.9.3 Demographic Reach and Achievements
20.9.4 Mergers and Acquisition
20.9.5 Certifications
20.10 Teva Pharmaceutical Industries Ltd.
20.10.1 Financial Analysis
20.10.2 Product Portfolio
20.10.3 Demographic Reach and Achievements
20.10.4 Mergers and Acquisition
20.10.5 Certifications
20.11 Gilead Sciences Inc.
20.11.1 Financial Analysis
20.11.2 Product Portfolio
20.11.3 Demographic Reach and Achievements
20.11.4 Mergers and Acquisition
20.11.5 Certifications
20.12 Novartis AG
20.12.1 Financial Analysis
20.12.2 Product Portfolio
20.12.3 Demographic Reach and Achievements
20.12.4 Mergers and Acquisition
20.12.5 Certifications
20.13 Cumberland Pharmaceuticals
20.13.1 Financial Analysis
20.13.2 Product Portfolio
20.13.3 Demographic Reach and Achievements
20.13.4 Mergers and Acquisition
20.13.5 Certifications
20.14 Organon LLC
20.14.1 Financial Analysis
20.14.2 Product Portfolio
20.14.3 Demographic Reach and Achievements
20.14.4 Mergers and Acquisition
20.14.5 Certifications
20.15 Lupin Ltd
20.15.1 Financial Analysis
20.15.2 Product Portfolio
20.15.3 Demographic Reach and Achievements
20.15.4 Mergers and Acquisition
20.15.5 Certifications
21 Systemic Sclerosis Market - Distribution Model (Additional Insight)
21.1 Overview
21.2 Potential Distributors
21.3 Key Parameters for Distribution Partner Assessment
22 Key Opinion Leaders (KOL) Insights (Additional Insight)
23 Company Competitiveness Analysis (Additional Insight)
23.1 Very Small Companies
23.2 Small Companies
23.3 Mid-Sized Companies
23.4 Large Companies
23.5 Very Large Companies
24 Payment Methods (Additional Insight)
24.1 Government Funded
24.2 Private Insurance
24.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us